Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteoporosis
FDA approves Actonel for once-a-week use
July 4th, 2002
The U.S. Food and Drug Administration (FDA) has approved a new 35 mg once-a-week dosage strength for Actonel (risedronate sodium tablets) for the prevention and treatment of postmenopausal osteoporosis. It will be available in mid-June 2002, by prescription only. Robert Lindsay, MD, PhD, chief of internal medicine at Helen Hayes Hospital, Professor of Clinical Medicine, Columbia University, and principal investigator of the Actonel once-a-week approval study, stated that patients and doctors always welcome effective new treatment choices, and now there is data showing that once-a-week dosing of Actonel is therapeutically equivalent to daily 5 mg dosing. ...
Source: Women's Health Weekly (2002-07-04)
|
